BlueRock Therapeutics

BlueRock Therapeutics

A biotechnology company developing engineered cell therapies for treating diseases in neurology, cardiology and autoimmunity.

BlueRock Therapeutics is a biotechnology company headquartered in New York City, New York that was founded by Lorenz Studer, Gordon Keller, Michael Laflamme, and Viviane Tabar.

Products

BlueRock is using their Cell plus Gene platform to produce cell therapies for replacement of damaged or degenerated tissue. BlueRock’s neurology pipeline focuses on Parkinson’s Disease and engineering microglia for other neurological disorders. Their cardiology pipeline includes cell therapy for heart failure using cardiomyocytes. For autoimmune diseases, the company is designing macrophage cell therapies. BlueRock is using ex vivo engineering to enable cells to produce enzymes, antibodies and other proteins with therapeutic benefit.

Cell therapy candidates are based on induced pluripotent stem (IPS) cell technology. The company’s approach is based on iPSC intellectual property invented by Shinya Yamanaka of Kyoto University in Japan and licensed from iPS Academia Japan, which manages iPSC IP.

Partnerships
Memorial Sloan Kettering Cancer Center and the Centre for Commercializing of Regenerative Medicine (CCRM)

BlueRock has partnerships with Memorial Sloan Kettering Cancer Center and Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM).

The McEwen Stem Cell Institute

In December 2018, BlueRock partnered with The McEwen Stem Cell Institute at the University Health Network (UHN) in Toronto’s MaRS Discovery District. A new pilot Good Manufacturing Practices (GMP) facility will open in 2019.

Funding
Series A

On December 12, 2016 BlueRock Therapeutics completed their series A funding round with $225 million in funding from Versant Ventures and Bayer AG.

Timeline

December 2016
Versant Ventures and Bayer provided US$225-million in financing to establish BlueRock Therapeutics
December 2016
BlueRock Therapeutics raises a $225,000,000 series A round from Versant Ventures and Bayer.
2016
BlueRock Therapeutics was founded by Gordon Keller.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
BlueRock Therapeutics Series A round December 2016
225,000,000
December 2016
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Emile Nuwaysir, Ph.D.

President and CEO

Gordon Keller, Ph.D.

Scientific Founder

Lorenz Studer, M.D.

Scientific Founder

Michael A. Laflamme, M.D., Ph.D.

Founding Investigator

Robert Deans, Ph.D.

CTO

Viviane Tabar, M.D.

Founding Investigator

Further reading

Title
Author
Link
Type
Date

$225M BlueRock Therapeutics "monster" a magnet for Canada's biotech sector

Financial Post

News

BlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute

BlueRock Therapeutics

Web

BlueRock Therapeutics: A regenerative medicine game-changer

Invest Ontario

Web

What You Need to Know About BlueRock Therapeutics

Mark Terry

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BlueRock Therapeutics
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial...
Research and Markets
December 31, 2020
www.prnewswire.com:443
/PRNewswire/ -- The "Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Cell...
Meagan Simpson
August 8, 2019
BetaKit
BlueRock Therapeutics is set to be fully acquired by German multinational pharmaceutical and life sciences company Bayer AG.
Ludwig Burger
August 8, 2019
U.S.
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.